Midostaurin (PKC412)

Catalog No.S8064 Synonyms: CGP 41251

Midostaurin (PKC412) Chemical Structure

Molecular Weight(MW): 570.64

Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.

Size Price Stock Quantity  
USD 110 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Purity & Quality Control

Choose Selective PKC Inhibitors

Biological Activity

Description Midostaurin (pkc412) is a multi-targeted kinase inhibitor, including PKCα/β/γ, Syk, Flk-1, Akt, PKA, c-Kit, c-Fgr, c-Src, FLT3, PDFRβ and VEGFR1/2 with IC50 ranging from 80-500 nM.
Targets
PKCα [1]
(Cell-free assay)
PKCγ [1]
(Cell-free assay)
PKCβ1 [1]
(Cell-free assay)
PKCβ2 [1]
(Cell-free assay)
PPK [1]
(Cell-free assay)
22 nM 24 nM 30 nM 31 nM 38 nM
In vitro

Midostaurin(pkc412) is a broad spectrum protein kinase inhibitor. Midostaurin(pkc412) interacts strongly with ATP binding sites of the conventional PKC-α, -β and -γ, PDGFRβ, VEGF-R2, VEGF-R1 and the cyclin-dependant kinase 1-cyclin B complex. Midostaurin(pkc412) inhibits the growth of various human and animal cell lines in vitro at similar submicromolar concentrations. Midostaurin(pkc412) also effectively inhibits the in vitro proliferation of glioblastoma and induced the accumulation of cells in G2/M and formation of giant nuclei with extensive fragmentation and apoptotic bodies. Midostaurin(pkc412) is able to reverse the p-glycoprotein-mediated multidrug resistance of tumor cells in vitro. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MV4-11 cells MVXDfZRwfG:6aXPpeJkh[XO|YYm= NHfQWVg4OiCq MVLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNWlQuOTFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JINmdGxidHn0[ZIu[my3ZTDhd5NigSxiSVO1NF0yOiCwTR?= MUWxPVY2PDRyOB?=
RS4-11 cells NYfJd3FDTnWwY4Tpc44h[XO|YYm= NXjifZZsOiCq M3XF[GlvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGG3dH;wbI9{eGixconsZZRqd25iaX6gbJVu[W5iUmO0MVEyKGOnbHzzJIFnfGW{IEKgbJJ{KGK7IHXs[YN1em:laHXtbYx2dWmwZYPj[Y5k\SCjc4PhfUwhUUN3ME2xN{BvVQ>? NYLzTZlmOTl4NUS0NFg>
CGTH-W-1 cell NEiwWXZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3\4c2lvcGmkaYTpc44hd2ZiaIXtZY4hS0eWSD3XMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Oi54NTFOwG0> M4DrTXNCVkeHUh?=
SW982 cell MmnyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MkD4TY5pcWKrdHnvckBw\iCqdX3hckBUXzl6MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS1MlU5KM7:TR?= M{e1OHNCVkeHUh?=
human EoL-1-cell cell MnrIS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NF\ESopKdmirYnn0bY9vKG:oIHj1cYFvKEWxTD2xMYNmdGxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Mj6wPEBvVQ>? NITtdIxUSU6JRWK=
MOLM-13 cells NWrvS4h6T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXrMWVlnPzJiaB?= NYHkU3FWUW6qaXLpeIlwdiCxZjDGUHQ{KEmWRDDo[ZRmem:8eXfveZMhdXW2YX70JIlvKGi3bXHuJG1QVE1vMUOgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSVIHHzd4F6NCCJSUWwQVAvODV3IN88US=> MoLHNlYxQDFyMkO=
KASUMI-1 cell NXe4OWNCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M1fsXmlvcGmkaYTpc44hd2ZiaIXtZY4hU0GVVV3JMVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB4MEG2JO69VQ>? M2Kz[nNCVkeHUh?=
NCI-H1755 cell M3TG[mdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MmrHTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3OVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB4MkezJO69VQ>? M2Lv[nNCVkeHUh?=
human MES-SA cell NFzT[IFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MmHiTY5pcWKrdHnvckBw\iCqdX3hckBOTVNvU1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA4PTR2IN88US=> MYPTRW5ITVJ?
human HCC1395 cell NH3JNFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NHPtfW5KdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{GzPVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjB6NEK4JO69VQ>? MVHTRW5ITVJ?
human D-336MG cell MoTzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYfJcohq[mm2aX;uJI9nKGi3bXHuJGQuOzN4TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlA5PzV2IN88US=> NGXoNHFUSU6JRWK=
CHP-212 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3TpdmlvcGmkaYTpc44hd2ZiaIXtZY4hS0iSLUKxNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvODh5N{Og{txO Ml3MV2FPT0WU
human KM12 cell M1zjRmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MkTPTY5pcWKrdHnvckBw\iCqdX3hckBMVTF{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6wPVI4PSEQvF2= MULTRW5ITVJ?
A204 cell M1HTbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXfJcohq[mm2aX;uJI9nKGi3bXHuJGEzODRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGwNFUzKM7:TR?= NWHQOWxnW0GQR1XS
CAL-51 cell NGOy[YFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NX3welM5UW6qaXLpeIlwdiCxZjDoeY1idiCFQVytOVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjFyN{C5JO69VQ>? NI\Td3FUSU6JRWK=
human A431 cell MljZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWrJcohq[mm2aX;uJI9nKGi3bXHuJGE1OzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkGxNlE3KM7:TR?= MYrTRW5ITVJ?
NCI-H650 cell MXTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIfVemVKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3IOlUxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5zMUewPEDPxE1? M2TLXnNCVkeHUh?=
A427 cell M2\ieWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIfhe3NKdmirYnn0bY9vKG:oIHj1cYFvKEF2MkegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlEyQTF6IN88US=> MUDTRW5ITVJ?
human 769-P cell NXzXW3dZT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV3mdoJ6UW6qaXLpeIlwdiCxZjDoeY1idiB5NkmtVEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOTJyOEKg{txO MoXxV2FPT0WU
SW1710 cell M1LHfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4jGcmlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzN{GwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4yOzNzNjFOwG0> M1O0dHNCVkeHUh?=
human H4 cell NFvYR2RIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEDpVYJKdmirYnn0bY9vKG:oIHj1cYFvKEh2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xN|k3OyEQvF2= MkjWV2FPT0WU
HT-1080 cell NHrYdXdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NGX2cnhKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjF3OUiyJO69VQ>? NVPpZ5RzW0GQR1XS
human PANC-03-27 cell MnH5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVuzNm44UW6qaXLpeIlwdiCxZjDoeY1idiCSQV7DMVA{NTJ5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6xOlAzKM7:TR?= MXLTRW5ITVJ?
A375 cells NVWwW4ZNS3m2b4TvfIlkcXS7IHHzd4F6 MX:3NkBp MkLDWI95cWOrdImgZYdicW6|dDDoeY1idiCDM{e1JINmdGy|IHHmeIVzKDd{IHjyd{BjgSClZXzsJJRqfGW{LXLseYUh[XO|YYmsJGlEPTB;MD6xPEDPxE1? MVixPVY2PDRyOB?=
human HOP-62 cell NGLENGFHfW6ldHnvckBie3OjeR?= NIHMNY9KdmirYnn0bY9vKG:oIHj1cYFvKEiRUD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOThyN{Og{txO MWnTRW5ITVJ?
human U031 cell MkXES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3HwS2lvcGmkaYTpc44hd2ZiaIXtZY4hXTB|MTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNVk3QThizszN NH[1ZppUSU6JRWK=
mouse BAF3 cells M4HwXnBzd2yrZnXyZZRqd25iYYPzZZk> MorSRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQV[zJINmdGy|IITyZY5{\m:{bXXkJJdqfGhiWl7GNVk5NU[JRmKxJINwdnO2coXjeEwhUUN3ME2wMlIh|ryP NInmcFMzOTl|NkW0Ni=>
human G-402 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2nHNmlvcGmkaYTpc44hd2ZiaIXtZY4hTy12MEKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlIxOjV|IN88US=> NEXiRndUSU6JRWK=
human G-361 cell M2PyUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXvJcohq[mm2aX;uJI9nKGi3bXHuJGcuOzZzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yNFg2OyEQvF2= M3nQS3NCVkeHUh?=
NCI-H810 cell MWHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXTJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KOEGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zOTB{NzFOwG0> M3jkOXNCVkeHUh?=
NCI-H2030 cell M1HMTmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3fn[GlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFMxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5{M{CwOkDPxE1? MYXTRW5ITVJ?
human HCT-116 cell NFzqbFBIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2niSmlvcGmkaYTpc44hd2ZiaIXtZY4hUEOWLUGxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN3Nkig{txO MmHQV2FPT0WU
human SNU-423 cell M2PqXWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3vaSGlvcGmkaYTpc44hd2ZiaIXtZY4hW06XLUSyN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN4NUeg{txO Mk\oV2FPT0WU
human SCC-4 cell MYPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUHYWIxRUW6qaXLpeIlwdiCxZjDoeY1idiCVQ1OtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOjN7Nkeg{txO M{\RbXNCVkeHUh?=
human SW48 cell M2PIN2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlfUTY5pcWKrdHnvckBw\iCqdX3hckBUXzR6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6yOlY5KM7:TR?= NXP2[lVtW0GQR1XS
human SF295 cell MkXnS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHjIO3RKdmirYnn0bY9vKG:oIHj1cYFvKFOIMkm1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zPzJ3NzFOwG0> MVzTRW5ITVJ?
MDA-MB-231 cell NHTz[5pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NEL4TIlKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0zOzFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1yLkK4NVAyKM7:TR?= Mnj5V2FPT0WU
A172 cell MX\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M3\j[GlvcGmkaYTpc44hd2ZiaIXtZY4hSTF5MjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuNlkyPSEQvF2= NGLWVW5USU6JRWK=
human BCPAP cell Ml2xS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NGrnXG5KdmirYnn0bY9vKG:oIHj1cYFvKEKFUFHQJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4zQTh5OTFOwG0> Moq5V2FPT0WU
human COLO-792 cell MmrqS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2jFO2lvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz23PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjJ7OUeyJO69VQ>? NXzWZmx{W0GQR1XS
human DU-145 cell NHHZcpRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUjJcohq[mm2aX;uJI9nKGi3bXHuJGRWNTF2NTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|E5QDlizszN M4G0eXNCVkeHUh?=
NCI-H2122 cell NHTSOFZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MX;Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkGyNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ{OEWg{txO M{TMVHNCVkeHUh?=
human SK-UT-1 cell NFXVU4dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MULJcohq[mm2aX;uJI9nKGi3bXHuJHNMNVWWLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlMzQTV{IN88US=> NGG5bYpUSU6JRWK=
LXF-289 cell M1rUeWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{XtWmlvcGmkaYTpc44hd2ZiaIXtZY4hVFiILUK4PUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzJ7NkWg{txO NVu2bGk1W0GQR1XS
human NCI-H1792 cell M3XBZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NHLhc4dKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVc6OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwM{OwPVYh|ryP M{LvTnNCVkeHUh?=
MCF7 cell NXnSfWN7T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXfocVdkUW6qaXLpeIlwdiCxZjDoeY1idiCPQ1[3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE4{OzJ5NDFOwG0> NYj3SHNYW0GQR1XS
HCT-15 cell NWLBNY1[T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYrJcohq[mm2aX;uJI9nKGi3bXHuJGhEXC1zNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuN|M1OzJizszN MlzYV2FPT0WU
human NCI-H358 cell MlnkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml6zTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEO1PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN3NUGg{txO M17WUHNCVkeHUh?=
human HLE cell NXfZRmVET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2XQT2lvcGmkaYTpc44hd2ZiaIXtZY4hUEyHIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zN|c2OiEQvF2= M3XDV3NCVkeHUh?=
human SW1088 cell M1nFWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGLZZW1KdmirYnn0bY9vKG:oIHj1cYFvKFOZMUC4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvOzN5OUeg{txO NW\1XmViW0GQR1XS
human K5 cell M1PDe2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEj1dXFKdmirYnn0bY9vKG:oIHj1cYFvKEt3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD6zOlE1QSEQvF2= MmG0V2FPT0WU
human SR cell NGLEU25Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MXPJcohq[mm2aX;uJI9nKGi3bXHuJHNTKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OC5|NkW3NUDPxE1? NHXMeWNUSU6JRWK=
human Calu-3 cell NGTFSoJIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUewXpVoUW6qaXLpeIlwdiCxZjDoeY1idiCFYXz1MVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN4OEK1JO69VQ>? MWHTRW5ITVJ?
human SK-MEL-30 cell MlLtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn7kTY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRVytN|Ah[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjN7OUGzJO69VQ>? M{D3XXNCVkeHUh?=
human SW780 cell M1ziO2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlOzTY5pcWKrdHnvckBw\iCqdX3hckBUXzd6MDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFEyPDJizszN NYDhRpE3W0GQR1XS
NCI-H1563 cell NXXmNlJPT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MXvJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMUW2N{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDF2OESg{txO NV3ldWRlW0GQR1XS
human MKN45 cell M3zxemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{HsfWlvcGmkaYTpc44hd2ZiaIXtZY4hVUuQNEWgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlQyQTNzIN88US=> NIfjOIxUSU6JRWK=
MDA-MB-157 cell NHXoZWZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWLRSmFqUW6qaXLpeIlwdiCxZjDoeY1idiCPRFGtUWIuOTV5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60NlAyPSEQvF2= M{HXOXNCVkeHUh?=
human NCI-H522 cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mk\1TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEWyNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPDJ|IN88US=> M1rEPXNCVkeHUh?=
human A2780 cell M4GwXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF3jdGJKdmirYnn0bY9vKG:oIHj1cYFvKEF{N{iwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE41PzVyMzFOwG0> MmDkV2FPT0WU
human A498 cell NWn2[YM3T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnHzTY5pcWKrdHnvckBw\iCqdX3hckBCPDl6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD60O|Y6OyEQvF2= MX;TRW5ITVJ?
human BxPC-3 cell MUDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVjJcohq[mm2aX;uJI9nKGi3bXHuJGJ5WENvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuOFk{PjZizszN NV;TPJI4W0GQR1XS
human A2058 cell MnzuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NE\sc2dKdmirYnn0bY9vKG:oIHj1cYFvKEF{MEW4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42Ojh2NDFOwG0> MWnTRW5ITVJ?
human PC-14 cell NFmyfWtIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NY\vZ|FzUW6qaXLpeIlwdiCxZjDoeY1idiCSQz2xOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVAvPTN6NUWg{txO NWHmOW5zW0GQR1XS
human KG-1 cell M3W2S2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MknvTY5pcWKrdHnvckBw\iCqdX3hckBMTy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MD61OVQyQSEQvF2= NYjHd2R1W0GQR1XS
human A375 cell MY\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV3vfXlWUW6qaXLpeIlwdiCxZjDoeY1idiCDM{e1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE42PjFyMzFOwG0> MXXTRW5ITVJ?
human SW1783 cell NWDFcYxET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NW\PZ|VZUW6qaXLpeIlwdiCxZjDoeY1idiCVV{G3PFMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjd|M{eg{txO NVrwSohSW0GQR1XS
human MKN1 cell M1S5UGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEXmcFdKdmirYnn0bY9vKG:oIHj1cYFvKE2NTkGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlg5PDF{IN88US=> M{m4XnNCVkeHUh?=
NCI-H1650 cell Mkj6S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmG3TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG2OVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0xNjh6OUG256CB|ryP MkO5V2FPT0WU
human HT-1376 cell NIrWPGdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= Mlv5TY5pcWKrdHnvckBw\iCqdX3hckBJXC1zM{e2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46OjlzODFOwG0> NHTB[GdUSU6JRWK=
SW872 cell MXXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NIj2XHhKdmirYnn0bY9vKG:oIHj1cYFvKFOZOEeyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46PDR3OTFOwG0> NH74dolUSU6JRWK=
human RT-112 cell NGDQSVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M135dmlvcGmkaYTpc44hd2ZiaIXtZY4hWlRvMUGyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NE46PzR6MzFOwG0> M1\Ed3NCVkeHUh?=
human HT-29 cell NXjPTVlyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= Mn7iTY5pcWKrdHnvckBw\iCqdX3hckBJXC1{OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVc6QTZizszN MojHV2FPT0WU
human U-266 cell MkWxS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2DMemlvcGmkaYTpc44hd2ZiaIXtZY4hXS1{Nk[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2wMlk5OzB{IN88US=> M3zvcXNCVkeHUh?=
human HEL cell NGTofGZIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIrKNJdKdmirYnn0bY9vKG:oIHj1cYFvKEiHTDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUCuPVg2OTdizszN MXjTRW5ITVJ?
human KU812 cell M{HwWWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MnnITY5pcWKrdHnvckBw\iCqdX3hckBMXThzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGuNVEyPjRizszN M1KyPHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Midostaurin(pkc412) may suppress tumor growth by inhibiting tumor angiogenesis (via its effects on the VEGF receptor tyrosine kinases) in addition to directly inhibiting tumor cell proliferation (via its effects on PKCs). This anti-angiogenic action may contribute to the antimetastatic and broad antitumor activity displayed by midostaurin(pkc412), as well as the synergy with cytotoxic agents, including doxorubicin, cyclophosphamide, cisplatin and gemcitabine. When given orally, the maximally tolerated dose for midostaurin(pkc412) is >300 mg/kg. [1]

Protocol

Cell Research:[2]
+ Expand
  • Cell lines: A549, NCI-H520
  • Concentrations: ~1.0 μM
  • Incubation Time: 24-72 h
  • Method: Each well is added with 5 mM WST-1 and 0.2 mM 1-methoxy PMS and the absorbance at 450 nm is measured by a Microplate Reader.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: Colo 205 colorectal tumors xenograft
  • Formulation: sterile water
  • Dosages: 50 mg/kg, 200 mg/kg, once daily
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (175.24 mM)
Ethanol 20 mg/mL warmed (35.04 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order:
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
4mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 570.64
Formula

C35H30N4O4

CAS No. 120685-11-2
Storage powder
Synonyms CGP 41251

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PKC Signaling Pathway Map

Related PKC Products

Tags: buy Midostaurin (PKC412) | Midostaurin (PKC412) supplier | purchase Midostaurin (PKC412) | Midostaurin (PKC412) cost | Midostaurin (PKC412) manufacturer | order Midostaurin (PKC412) | Midostaurin (PKC412) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID